Navigation Links
Corgenix Reports Second Quarter Fiscal 2010 Financial Results

DENVER, Feb. 11 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, today filed its 2nd quarter Form 10-Q and reported its financial results. The report disclosed that the company's revenues slightly declined during the quarter but slightly increased for the six months ended December 31, 2009. Some of the results highlighted by the report are as follows:

  • Revenues for the quarter decreased $35,574 or 1.8% vs. the prior year's comparable quarter
  • Total operating expenses decreased $147,774 or 12.2% vs. the prior year's comparable quarter
  • Operating income for the quarter was $12,395 vs. an operating loss of $56,223 for the prior year's comparable quarter
  • Net loss decreased to $83,841 or 68.8% in the current quarter from $268,374 in the prior year's comparable quarter

Douglass Simpson, Corgenix CEO and President, stated, "Compared to the prior year, revenues softened slightly in the second quarter, largely due to a decrease in our private label (OEM) and contract manufacturing business sectors, partially offset by slight growth in our direct product sales. We have recently added new contract manufacturing customers and are continuing to focus on the expansion and strengthening of this segment of our business."

The company further noted that the financial performance for the quarter was not as strong as expected, with continued weakness in core product revenue. The company continues to remain hopeful that Fiscal Year 2010 revenues will exceed those of the prior fiscal year, even though there can be no assurance that this will be the case.

Second Quarter 2010 Conference Call Details

Corgenix invites all those interested in hearing management's discussion of second quarter results to join a shareholders conference call on Thursday, February 11, 2010, at 4:00 PM EST (2:00 PM MST). Interested parties can join the call by dialing (800) 862-9098. International participants may access the call by dialing +1 785-424-1051. The conference code is "CORGENIX". A replay will be available for 30 days following the call by dialing (800) 283-4641 for domestic participants and +1 402-220-0851 for international participants.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at

Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

                           SUMMARY OF FINANCIAL HIGHLIGHTS
      ($000 of U.S. dollars except shares outstanding and per share amounts)
                                   OPERATIONAL DATA
                       Three Months Ended              Six Months Ended
                       ------------------              ----------------
                  December 31,     December 31,   December 31,    December 31,
                       2009            2008           2009            2008
                   (unaudited)     (unaudited)    (unaudited)     (unaudited)
                   -----------     -----------    -----------     -----------
    Net sales          $1,959          $1,995         $4,004          $3,997
     profit             1,075           1,154          2,191           2,261
     expenses           1,063           1,210          2,094           2,411
     (loss)                12             (56)            96            (150)
    Net loss              (84)           (268)           (91)           (609)
    Basic and
     loss per
     share             $(0.00)         $(0.01)        $(0.00)         $(0.02)
     outstanding   31,033,209      30,280,155     30,669,532      30,186,124
                              SUMMARY BALANCE SHEET DATA
                                    (in thousands)
                                   December 31, 2009     June 30, 2009
                                      (unaudited)         (audited)
                                       ----------         ---------
    Cash                                   $662              $785
    Working capital                       2,043             2,013
    Total assets                          6,367             6,906
    Long-term debt                          607               744
    Total stockholders' equity            3,052             3,113

SOURCE Corgenix Medical Corporation



SOURCE Corgenix Medical Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Corgenix AspirinWorks(R) Test Recognized in POLYCAP Study at ACC.09
2. Corgenix, Tulane Announce Award of NIH Grant Extending Hemorrhagic Fever Virus Product Development Program
3. Corgenix to Host Conference Call to Discuss Fiscal 2010 First Quarter Results
4. Corgenix Reports Financial Results for First Quarter of Fiscal 2010
5. Corgenix and BG Medicine Announce Supply Agreement for BGM Galectin-3(TM)
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. Spherix Reports Second Quarter Earnings
8. Tapestry Reports Second Quarter 2007 Results
9. Callisto Reports on Second-Quarter 2007 Milestones
10. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
11. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
Post Your Comments:
(Date:6/23/2016)... 2016 Research and Markets has ... Global Analysis (United States, China, Japan, Brazil, United Kingdom, ... their offering. Surgical ... business planners, provides surgical procedure volume data in a ... an in-depth analysis of growth drivers and inhibitors, including ...
(Date:6/23/2016)... -- The Biotechnology industry might still be ... opportunities to investors. assesses the recent performances of ... XON ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ... complimentary trade alerts at: ...
(Date:6/23/2016)... Leading BioSciences Inc., a clinical-stage biopharmaceutical ... from a breakdown of the mucosal barrier, today ... as chief executive officer. Mr. Doyle, a ... and board of directors, previously served as chief ... provide continued leadership and strategic direction to the ...
Breaking Medicine Technology:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... edge technology to revolutionize the emergency ambulance transport experience for the millions of ... of how Uber has disrupted the taxi industry through the use of technology. ...
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
Breaking Medicine News(10 mins):